Core Insights - Georgia Power is focused on helping customers manage energy bills and stay cool during the summer by providing practical energy efficiency tips and resources [1] Energy Efficiency Programs - The EASE Program offers free home upgrades such as LED light bulbs and attic insulation for qualifying customers, particularly those with incomes at or below 200% of federal poverty guidelines [2] - Customers can utilize the My Power Usage tool to monitor energy consumption and receive alerts when they exceed their usage targets [3] Community Assistance Resources - Georgia Power provides a directory of local resources for assistance with utilities, food, and shelter, accessible through their website [4] - The company partners with community organizations to offer support for rent and utilities, including the Project Share initiative [5] Commitment to Customer Empowerment - Georgia Power emphasizes the importance of energy-saving tips and community support to help customers navigate summer energy challenges effectively [6] - The company maintains a diverse energy generation mix, including renewables, and offers rates below the national average [7] Additional Energy-Saving Tips - Recommendations include changing air filters regularly, sealing windows and doors, using cold water for laundry, and utilizing appliances during off-peak hours [8]

Funding Supports Advancement of Obesity Program and Strategic Business Development Initiatives Advancement of novel next-generation MC4R long-acting peptides and oral small molecules IND applications planned for Q4 2025; clinical data expected H1 2026 Phase 1 SAD/MAD studies to include patients with hypothalamic obesity Ocular asset collaborations expected in Q2 and Q3 2025CRANBURY, N.J., May 7, 2025 /PRNewswire/ -- Palatin Technologies, Inc. (the "Company" or "Palatin") (NYSE American: PTN), a biopharmac ...

Recursion Pharmaceuticals (RXRX -15.70%) didn't have a fine start to the working week on Monday, at least as far as its stock was concerned. Investors traded out of it following the clinical-stage biotech's first-quarter earnings release and business update, and the share price was down by 15% in mid-session trading. The S&P 500 index was doing comparatively better, with a 0.3% decline. Light revenue and a deepening net lossFor the quarter, Recursion -- which although a clinical-stage company earns some coi ...